Has Arbi Ohanian, MD received payments from drug or device companies?

Yes. Drug and device makers reported $43,033 in general payments to Arbi Ohanian, MD across 281 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Arbi Ohanian, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Arbi Ohanian, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Arbi Ohanian, MD

Neurology · Pasadena, CANPI 1982894606

Payments from drug & device makers

$43,033in general payments, 2019–2025

Across 281 payments — averaging $153.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Ipsen Innovation$33K
Boehringer Ingelheim$4K
AbbVie$2K
UCB, Inc.$495
AstraZeneca$429
Novartis$377
plus $4K from 45 others

What the payments were for

Food & beverage$6,805100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Ipsen Innovation	15	$32,534
Boehringer Ingelheim	1	$3,693
AbbVie(2 entities)	70	$1,514
UCB, Inc.	19	$495
AstraZeneca(2 entities)	14	$429
Novartis	16	$377
Abbott	5	$365
Eisai Inc.	13	$337
Neurocrine Biosciences, Inc.	9	$256
Lundbeck LLC	10	$243
Teva Pharmaceuticals USA, Inc.	9	$223
Genentech USA, Inc.	4	$208
Acorda Therapeutics, Inc	9	$203
Pfizer	8	$177
Lilly USA, LLC	7	$175
Johnson & Johnson	1	$125
SK Life Science, Inc.	5	$121
Amgen	4	$95
Hill-rom Company, Inc	1	$90
Amneal Pharmaceuticals LLC	4	$82
Neurelis, Inc.	4	$76
ANI Pharmaceuticals, Inc.	3	$72
Alnylam Pharmaceuticals Inc.	3	$69
Sunovion Pharmaceuticals Inc.	4	$68
Jazz Pharmaceuticals Inc.	2	$65
Livanova USA, Inc.	3	$64
Adamas Pharmaceuticals, Inc.	3	$63
Merz Pharmaceuticals, LLC	2	$63
Sumitomo Pharma America, Inc.	3	$58
Tanabe Pharma America, Inc.	2	$57
MDD US Operations, LLC	3	$57
Biohaven Pharmaceuticals, Inc.	2	$51
Biogen	2	$48
Upsher-smith Laboratories LLC	2	$48
Nevro Corp.	2	$46
EMD Serono, Inc.	2	$42
Immedica Pharma US, Inc.	1	$41
Biohaven Pharmaceutical Holding Company Ltd.	1	$33
Neuropace, Inc.	1	$32
Mallinckrodt Enterprises LLC	1	$32
Xeris Pharmaceuticals, Inc.	1	$24
GE HealthCare	1	$24
Amylyx Pharmaceuticals, Inc.	1	$23
Terumo BCT, Inc.	1	$21
Tonix Medicines, Inc.	1	$20
Kyowa Kirin, Inc.	1	$19
Portola Pharmaceuticals, LLC	1	$17
E.r. Squibb & Sons, L.L.C.	1	$15
Assertio Therapeutics, Inc.	1	$14
Scilex Pharmaceuticals Inc.	1	$14
Azurity Pharmaceuticals, Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$43,033 in reported general payments places this provider in the 85th percentile of 1,996 neurology providers in California.

See all neurology providers in California →

Medicare billing

Part B allowed, 2024

$82,738

Medicare patients

240

Services billed

926

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Oxcarbazepine	11	$554
Levetiracetam	21	$491
Escitalopram Oxalate	22	$394
Nortriptyline Hcl	13	$380
ClopidogrelClopidogrel Bisulfate	47	$316
Gabapentin	15	$298
Atorvastatin Calcium	12	$150

Paid to pharmacies, not to this prescriber.

Other neurology in Pasadena

Jesse CarrPasadena$5.4M
Timothy CloughesyLos Angeles$33.1M
Jack FlorinFullerton$13M
David KudrowSanta Monica$12.8M
John Ravitsla Jolla$8.4M
Perminder BhatiaFresno$8.3M
Perry ShiehLos Angeles$8.2M
Benjamin FrishbergCarlsbad$8.2M
Bruce CreeSan Francisco$8M
Lawrence RechtPalo Alto$6.6M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →